In vitro cytokine release assays for predicting cytokine release syndrome: The current state-of-the-science. Report of a European Medicines Agency Workshop

Cytokine

Volumn 51, Issue 2, 2010, Pages 213-215

  Vidal, Jean Marc ^a   Kawabata, Thomas T ^b   Thorpe, Robin ^c   Silva Lima, Beatriz ^d   Cederbrant, Karin ^e   Poole, Stephen ^c   Mueller Berghaus, Jan ^f   Pallardy, Marc ^g   Van der Laan, Jan Willem ^h  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d UNIVERSITY OF LISBON   (Portugal)

^e ASTRAZENECA R AND D   (Sweden)

^f PAUL EHRLICH INSTITUT   (Germany)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; MEMBRANE ANTIGEN; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; OKT 3; RITUXIMAB; TGN 1412; THYMOCYTE ANTIBODY; CYTOKINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BINDING AFFINITY; CALIBRATION; CELL TYPE; CLINICAL ASSESSMENT TOOL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENDOTHELIUM CELL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INTERMETHOD COMPARISON; MULTIPLE ORGAN FAILURE; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TUMOR LYSIS SYNDROME; VALIDATION PROCESS; ADVERSE DRUG REACTION; DRUG DEVELOPMENT; PROCEDURES; SECRETION (PROCESS); SYNDROME;

CYTOKINES; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; SYNDROME;

EID: 77955770126     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.04.008     Document Type: Conference Paper

References (5)

1. Expert group on phase one clinical trials: final report (Chairman: Professor Gordon Duff); 7 December 2006. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publicati onsPolicyAndGuidance/DH_063117.
2. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., et al. " Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007, 179(5):3325-3331.
3. Findlay L., Eastwood D., Stebbings R., Sharp G., Mistry Y., Ball C., et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods 2010, 352(1-2):1-12.
4. Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. CPMP/ICH/286/95 (ICH M 3 (R2)).
5. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. CHMP/SWP/28367/07.